Schwab Strategic Trust Schwab Ariel ESG ETF (ARCA: SAEF)

Ultime notizie per Schwab Strategic Trust Schwab Ariel ESG ETF (ARCA:SAEF)

Industrials

Consumer Cyclical

Technology

Financial Services

Healthcare

Communication Services

Real Estate

Consumer Defensive

Basic Materials

The fund invests primarily in exchange-traded equity securities of U.S. companies that have been evaluated based on certain environmental, social and governance (ESG) criteria. The fund typically invests in exchange-traded securities of small- and mid-capitalization companies which are companies with capitalizations within the range of the Russell 2500 Index, as measured at the time of purchase however, the fund may invest in exchange-traded securities of companies outside the stated range.

Onespaworld Holdings Ltd.

Brink's Co/the

Lindblad Expeditions Holdings Inc

Norwegian Cruise Line Holdings Ltd.

Fiserv Inc.

Nvent Electric Plc

Kkr & Co. Inc. Class A

Goldman Sachs & Co

Zebra Technologies Corp

Resideo Technologies Inc

Northern Trust Corp.

First American Financial Corp

State Street Institutional US Government Money Market Fund

Prestige Consumer Healthcare Inc

Middleby Corp/the

Schwab Ariel ESG ETF

Nanortalik,,Greenland,-,27,August,2024:,Close,Up,View,Of

Equities

Mid Cap

News

Movers

CRUZ

NCLH

SAEF

Strategie in evoluzione nel settore crocieristico: cessioni e nuovi accordi. Come cambia il futuro della compagnia e il mercato.

Norwegian Cruise Line: 4 navi lasciano la flotta, ma l&#39;espansione continua

Schwab Strategic Trust Schwab Ariel ESG ETF

Sen. Elizabeth Warren (D-Mass.) warned Tuesday that millions of borrowers face "a financial scarlet letter" as the Trump administration <a href="https://www.benzinga.com/25/05/45214832/with-16-trillion-owed-by-427-million-student-loan-borrowers-federal-government-resumes-collections-after-5-years-as-delinquencies-reach-record-high-transunion-warns">ends a five-year pause and restarts collections</a> on defaulted federal student loans.
What Happened: The policy, announced May 5, allows the Education Department to seize wages, intercept tax refunds and eventually garnish Social Security checks, putting home purchases and job prospects at risk, Warren wrote in a blog post released ahead of a meeting with Education Secretary Linda McMahon.
The New York Federal Reserve says 8.04% of education-loan balances slipped into serious delinquency in the first quarter, projecting a surge in defaults this summer. Roughly 2.2 million borrowers have already seen credit scores plunge more than 100 points since negative reporting resumed last fall.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Numbers don't lie. Read my breakdown on the real impact of Trump's policies on student borrowers in <a href="https://twitter.com/SenateBanking?ref_src=twsrc%5Etfw">@SenateBanking</a>&#39;s latest Substack post here: <a href="https://t.co/Vi0jJ1BOl8">https://t.co/Vi0jJ1BOl8</a>
&mdash; Elizabeth Warren (@SenWarren) <a href="https://twitter.com/SenWarren/status/1932497809376178522?ref_src=twsrc%5Etfw">June 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&#8220;A damaged credit score is a financial scarlet letter that can follow consumers for years,&#8221; warns Warren.
See also: <a href="https://www.benzinga.com/news/politics/25/06/45879240/secretatry-of-state-marco-rubio-pushes-sanctions-probe-into-harvard-over-ties-to-blacklisted-chinese-entity-report">Secretatry Of State Marco Rubio Pushes Sanctions Probe Into Harvard Over Ties To Blacklisted Chinese Entity: Report</a>
She goes on to explain that borrowers with damaged credit often shell out thousands more in interest on car loans, if lenders approve them at all. Banks may then deny their mortgage applications, pushing them into pricey rentals that build no equity. Utility companies, cell-phone carriers, and landlords also demand hefty security deposits that customers with solid credit skip.
&#8220;Nearly half of all employers now run credit checks, meaning damaged credit can cost someone a job opportunity,&#8221; she says.
Why It Matters: McMahon defended the crackdown, saying collections restore accountability and protect taxpayers. While her department <a href="https://www.benzinga.com/25/05/45601283/social-security-checks-could-shrink-for-450000-retirees-as-government-resumes-seizing-benefits-over-student-loan-defaults">temporarily paused</a> Social Security offsets, it plans to resume them later this summer alongside administrative wage garnishment.
Warren also blasted a House-passed spending bill in her blog, stating that it would collapse the existing patchwork of <a href="https://www.benzinga.com/personal-finance/25/04/44890297/married-borrowers-could-see-major-changes-to-student-loan-payments-whats-happening-with-idr-plans">income-driven repayment plans</a> into two options with less-generous terms, potentially lengthening repayment periods and raising monthly bills.
Warren last week vowed to fight President Donald Trump's "One Big Beautiful Bill Act," saying it would gut the Consumer Financial Protection Bureau by <a href="https://www.benzinga.com/news/politics/25/06/45854511/elizabeth-warren-calls-trumps-tax-bill-ugly-for-targeting-cfpb-says-it-returned-21-billion-to-cheated-americans">cutting</a> its Federal Reserve funding. She also argued the legislation would <a href="https://www.benzinga.com/news/politics/25/06/45785851/elizabeth-warren-says-trumps-one-big-beautiful-bill-will-rip-away-health-coverage-from-16-million-americans-just-so-jeff-bezos-can-buy-a-third-ya">strip health coverage</a> from 16 million Americans and shower billionaires like Jeff Bezos and Mark Zuckerberg with tax breaks.
Photo courtesy: Sheila Fitzgerald / Shutterstock.com
Read next: <a href="https://www.benzinga.com/markets/tech/25/06/45878991/mark-zuckerberg-is-handpicking-a-superintelligence-team-to-lead-metas-agi-race-after-llama-4-letdown-report">Mark Zuckerberg Is Handpicking A &#8216;Superintelligence&#8217; Team To Lead Meta&#8217;s AGI Race After Llama 4 Letdown: Report</a>

Education

Politics

Legal

General

Elizabeth Warren Says Millions Face 'Financial Scarlet Letter' As Trump Restarts Student-Loan Collections: '...Can Cost Someone A Job Opportunity'

Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>), a clinical-stage biopharmaceutical company, today announced preclinical data highlighting the potential of soquelitinib to treat systemic sclerosis will be presented today in a poster session at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is taking place June 11-14, 2025 in Barcelona. The poster will be presented by Gonçalo Boleto, M.D., MSc, a rheumatologist at Centro Académico de Medicina de Lisboa, Portugal. It was selected as a top 10 abstract by the Emerging EULAR Network (EMEUNET), a network of young rheumatologists and researchers in the field of rheumatology in Europe and beyond.

CRVS

Corvus Pharma To Present Preclinical Data Highlighting Potential Of Soquelitinib To Treat Systemic Sclerosis At EULAR 2025 Congress

WIIM

STLD

Shares of steel companies are trading lower following a report suggesting the US and Mexico are nearing a deal that would remove the Trump Administration's 50% tariffs on steel imports up to a certain volume.

D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) with a Buy and maintains $10 price target.

Price Target

Analyst Ratings

CRVO

D. Boral Capital Maintains Buy on CervoMed, Maintains $10 Price Target

Lottery.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRY#NASDAQ">LTRY</a>, LTRYW))) ("Lottery.com" or "the Company"), a leading technology company transforming the intersection of gaming, sports and entertainment, announces the signing of an amended Stock Purchase Agreement ("SPA") for its planned acquisition of Nook Holdings Limited ("Nook"), a pioneering sports, health and&nbsp;wellness incubator based in Dubai, United Arab Emirates.
The acquisition, valued at approximately $2.5 million USD, is an all-cash deal, underscoring Lottery.com's strategic commitment to global growth and innovation in sports and wellness. Upon completion, the Company will control ninety percent (90%) of Nook. The deal is expected to close on or before June 30, 2025.
Sports.com: A Global Launchpad for Sports Startups
Upon completion of the acquisition, the Company will operate segments of its international sports business from within the Nook premises at One JLT, transforming the space into a gateway for sports innovation, investment and integration. The site will continue to function as both a premium co-working space and a business incubator, connecting early-stage sports businesses with the broader Sports.com ecosystem.

LTRY

Lottery.com Signs Amended Stock Purchase Agreement For $2.5M All-Cash Acquisition Of Nook Holdings, Securing 90% Stake by June 30, 2025

Lottery.com To Acquire 90% Stake In Dubai-Based Sports Incubator Nook For $2.5M

Fiscal 2026 First Quarter Financial Highlights
<ul>
<li>Annual Recurring Revenue (ARR): Total ARR was $925 million, an increase of 30% year-over-year. SaaS ARR was $574 million, an increase of 39% year-over-year.</li>
<li>Revenue: Total revenue was $230 million, an increase of 23% year-over-year. Subscription revenue was $215 million, an increase of 27% year-over-year.</li>
<li>Operating Income (Loss): GAAP operating loss was $(185) million, or (80)% of revenue, compared to $(68) million, or (36)% of revenue in fiscal Q1 2025. Adjusted income from operations was $24 million, or 10% of revenue, compared to $19 million, or 10% of revenue in fiscal Q1 2025.</li>
</ul>

SAIL

SailPoint Reported Q1 ARR Of $925M, Up By 30% YoY, SaaS ARR Of $574M, Up By 39% YoY

CHWY: -6% &#x7C; <a href="https://www.benzinga.com//node/45879582">Chewy Q1 2025 Adj. EPS $0.35 Beats $0.34 Estimate, Sales $3.12B Beat $3.08B Estimate</a>
&nbsp;
GTLB: -15% &#x7C; <a href="https://www.benzinga.com//node/45879617">GitLab shares are trading lower after the company reported Q1 financial results and issued Q2 sales guidance with its midpoint below estimates.</a>
&nbsp;
HSDT: 150% &#x7C; <a href="https://www.benzinga.com//node/45879580">Helius Medical Technologies Announces Authorized Claim For Payment For PoNS Device From Aetna Healthcare.</a>

Trading Ideas

CHWY

GTLB

HSDT

Market-Moving News for June 11th

ITRM

Iterum Therapeutics Partners With EVERSANA To Launch ORLYNVAH In US By Q4 2025, Targeting Hard-To-Treat UTIs

Lottery.com Signs Amended Stock Purchase Agreement For Planned Acquisition Of Nook Holdings Valued At ~$2.5M; Upon Completion, Co. Will Control 90% Of Nook

Guidance

SailPoint Raises FY2026 Adj EPS Guidance from $0.14-$0.18 to $0.16-$0.20 vs $(0.10) Est; Raises FY2026 Sales Guidance from $1.02B-$1.03B to $1.03B-$1.04B vs $854.21M Est

AEVA

Aeva Achieves TISAX Level 2 Certification, Strengthening Info Security Standards For Global Automotive Industry

<ul>
<li>Baker Hughes awarded P&amp;A agreement based on Mature Assets Solutions portfolio</li>
<li>Agreement will enable Equinor to drive efficiencies, industrialize P&amp;A operations through end-to-end integration</li>
<li>Award marks first project as part of multi-year frame agreement for integrated well services</li>
</ul>
HOUSTON and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), an energy technology company, will provide Equinor plug and abandonment (P&amp;A) services in the Oseberg East field on Norway's continental shelf. Baker Hughes' Mature Assets Solutions team will lead the integrated P&amp;A campaign planning phase, as well as delivering integrated P&amp;A services in execution across several wells in the North Sea.

Baker Hughes To Provide Equinor P&A Services In Oseberg East Field On Norway's Continental Shelf

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11073944/Hipine-0611-900x600-1.png" alt="" class="wp-image-14241" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11073944/Hipine-0611-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11073944/Hipine-0611-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11073944/Hipine-0611-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The maker of gold watches is grappling with high production costs and weak sales growth following a big jump in prices of the precious metal
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Hipine has filed for a Hong Kong IPO, reporting falling profits and a sharp slowdown in its revenue growth last year</li>
<li>High gold prices are raising the watch maker's raw material costs and could dampen demand for its products, especially in China's current weak economy</li>
</ul>
Time may be its core business, but gold watch maker&nbsp;Shenzhen Hipine Precision Technology Co. Ltd.&nbsp;seems to have lost its sense of timing by filing for a Hong Kong IPO last week.
Gold prices have been soaring lately as central banks and investors globally stock up on the metal as a hedge against economic uncertainty. That's creating headaches for companies that make gold accessories, including watches, like Hipine. They can try to charge higher prices to offset their rising material costs, but that can scare away consumers. That dilemma becomes doubly poignant in a weak economy like China's right now, where consumers are reining in their spending, especially for expensive, discretionary items like gold accessories.
Despite those factors working against it, the maker of Hipine brand gold watches went ahead and filed for a Hong Kong listing. The road to market is sure to be bumpy, as the company looks set to face plenty of investor skepticism about its ability to grow.
For starters, Hipine's revenue increased just 2.5% to 457 million yuan ($64 million) last year from 2023 as gold prices marched higher, hitting records, according to its&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107421/documents/sehk25060400246.pdf">listing document</a>. That's a significantly slower pace than its 38% revenue growth for 2023, when gold prices were lower and China was still enjoying a post-pandemic rebound and wave of "revenge spending."
But its ability to grow sales at all last year was no mean feat, considering that gold consumption in China decreased nearly 10% in 2024. In particular, purchases of gold jewelry, which accounts for half of total consumption of the metal in the country, dropped by more than a quarter last year. By contrast, buying of gold bars and coins jumped at a similar rate.
The disparity between the two categories of products reflects different attitudes between consumers and investors towards gold in a difficult economy. Consumer sentiment in China is generally quite lackluster, and particularly weak for luxury items like gold-covered products that typically sell for big mark-ups above their material costs. Key products for Hipine — which says it is the largest maker of gold watches in China — retailed for as much as nearly 30,000 yuan apiece at the end of last year, according to its listing document.
But interest in the precious metal among investors may be stronger than ever as they seek safe-haven assets to hedge against heightened economic uncertainty. Such demand fueled a 28% rally in the price of the most active gold contract on the Shanghai Futures Exchange last year, which helped drive demand for products like gold bars, whose prices are basically the same as the content of the gold they contain. But rising gold prices only further suppress demand for consumer-related products like watches and jewelry.&nbsp;&nbsp;&nbsp;
The sharp increase in gold prices has left Hipine grappling with higher raw material costs and weak sales growth. A 20% increase in raw material prices last year would have sent the company into the red, according to an estimate in its prospectus.
<h4 class="wp-block-heading">Wriggle room</h4>
Yet the company has some wriggle room to keep its costs down. It doesn't recognize the cost of the gold it buys until it actually sells products using that material. That means if it holds a significant amount of gold that it procured earlier at lower prices, and sells products containing that gold later, the company can keep its raw material costs from growing rapidly. Hipine can also use this discrepancy to curb its price increases, helping it to retain buyer interest.
This method of cost recognition apparently helped Hipine improve its gross profit margin last year. Its raw material costs actually decreased a bit, and it also slashed spending on direct labor and overhead expenses. As a result, the company's gross profit grew 15% last year, much faster than its 2.5% revenue growth.
To protect itself from rising gold prices, Hipine also borrows gold from banks. Such schemes allow the company to secure gold at lower prices if its value increases later, though it pays the lenders interest in cash. It can then use the borrowed gold to make watches and use part of revenue from the sales of the products to buy the same amounts of gold and return it to the banks when the borrowing periods expire.
This strategy works if gold rises in value, allowing Hipine to mark up the prices of its products significantly enough to cover all costs for gold loans and still make some profits. The downside is that if gold prices go up, the company needs to record a valuation loss on its gold loans.
That was one reason Hipine's net profit slipped 5.3% to 49.3 million yuan last year, despite the improvement in its gross profit margin. It booked an 8.2 million yuan valuation loss on its gold loans for the year, more than four times the amount for 2023. The company's operating expenses also increased, and impairment losses related to trade receivables further ate into its earnings.
The bottom line is that Hipine's performance last year probably won't awe anyone. And its future prospects don't look much shinier. Beijing is trying hard to stimulate domestic consumption, which, if successful, could reignite Hipine's revenue growth. But highly discretionary and low value-added items like gold jewelry and watches don't seem to be high on the government's list of what it wants consumers to buy, with other products like home appliances and cars getting higher priority.
What's more, high gold prices are probably here to stay, at least for the foreseeable future, as trade tensions and other geopolitical factors keep investors and central banks around the world jittery. Gold consumption in China fell nearly 6% year-on-year in the first quarter of this year.
Shares of listed jewelry makers can give investors some idea about how Hipine's stock might be valued. Among them,&nbsp;Chow Tai Fook's&nbsp;(1929.HK)&nbsp;shares trade at a price-to-earnings (P/E) ratio of 26, while&nbsp;Chow Sang Sang&nbsp;(0116.HK) is far lower at about 7. A P/E ratio somewhere in the middle of the two, say 17, would give Hipine a market capitalization of more than $100 million, based on its 2024 net profit.
But the two gold jewelry companies are much larger and more established than Hipine, which was founded in 2013. And their product prices are far more based on the cost of the gold they contain, meaning their products can hold their value better than watches that aren't from top-tier brands like Rolex.
So we wouldn't be surprised if Hipine ends up with a lower valuation, especially as its growth prospects look dull in the near term, unlike its glittery products.&nbsp;

Commodities

IPOs

Opinion

High Gold Prices May Take The Shine Off Hipine As It Seeks Hong Kong IPO

Lockheed Martin shares are trading lower after the company after the  Pentagon reportedly reduced its Air Force F-35 fighter jet request from 48 to 24 aircraft.

SailPoint Sees Q2 Adj EPS $0.04-$0.05 vs $(0.01) Est; Sees Sales $242.000M-$244.000M vs $231.96M Est

Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) Q2 expected to be below $0.15 vs $0.30 Est. sees Q2 sales of $1.380 billion-$1.410 billion vs $1.42 billion analyst estimate.

VSCO

Victoria's Secret Q2  expected to be below $0.15 vs $0.30 Est; Sees Q2 Sales $1.380B-$1.410B vs $1.42B Est

Victoria's Secret Revised FY25 Adjusted Operating Income Guidance To $270M-$320M (Prior View: $300M-$350M); Company Sees Estimated Net Tariff Impact Of Approximately $50M

Partnership aims to develop first-in-class, small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases
Deep Apple is eligible to receive up to $812 million, including an upfront payment, research costs, and milestone payments
SOUTH SAN FRANCISCO, Calif., June 11, 2025 /PR Newswire/ – Deep Apple Therapeutics, Inc. announced today a research collaboration and exclusive worldwide license agreement with Novo Nordisk to discover, develop, and commercialize oral small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases, including obesity.
Under the terms of the agreement, Deep Apple will discover and optimize compounds using its proprietary drug discovery platform, which combines machine-learning-powered virtual screening with structural biology enabled by cryo-electron microscopy (cryo-EM) to dramatically improve speed, quality, and novelty in lead generation and optimization.
Novo Nordisk will receive exclusive global rights to develop, manufacture, and commercialize the resulting compounds and products in all indications. Both companies will collaborate on the research plan, with program handoff to Novo Nordisk occurring immediately prior to the start of IND-enabling studies.
Deep Apple is eligible to receive an upfront payment, research costs, and milestone payments from Novo Nordisk. In total, Deep Apple will be eligible to receive up to $812 million in payments, as well as potential royalties on sales of any products that emerge from the collaboration.
The target is a non-incretin G-protein coupled receptor (GPCR) that is well-suited for Deep Apple's platform, which captures the dynamics and motion of GPCRs and other proteins in different conformations to reveal novel pockets that can be docked with Deep Apple's proprietary virtual libraries.

Deep Apple Therapeutics Collaborates With Novo Nordisk To Discover, Develop, And Commercialize Oral Small Molecule Therapeutics Directed At Non-Incretin GPCR Target For Cardiometabolic Diseases

Certification Reinforces Aeva's Maturity to Support Global OEMs with Secure, Automotive Qualified Sensing Solutions for Advanced Vehicle Automation

AVEA

Aeva Secures TISAX AL2 Certification, Enhancing Info Security For Global Automotive Partners

Comments

Schwab Strategic Trust Schwab Ariel ESG ETF

Notizie

Ultime notizie per Schwab Strategic Trust Schwab Ariel ESG ETF (ARCA:SAEF)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO